Research progress and perspectives of noncoding RNAs in adrenocortical carcinoma: A review

Changfen Xu,Peiyao Xu,Jiaqi Zhang,Sheng He,Tingting Hua,Aiwu Huang

DOI: https://doi.org/10.1097/md.0000000000036908

IF: 1.6

2024-02-03

Medicine

Abstract:Adrenocortical carcinoma (ACC) is a rare malignancy characterized by invasive biology and underlying endocrine activity. [ 1–3 ] The incidence of ACC is approximately 0.7 to 2.0 per million people, with a bimodal age distribution and a slightly higher incidence in women than that in men. [ 4 , 5 ] Most ACC patients have no obvious early symptoms and invaded surrounding tissues or organs at the time of diagnosis, and even have distant metastases. [ 6 , 7 ] In the majority of ACC patients, overproduction of estrogen, androgens, glucocorticoids, or aldosterone are observed. [ 8 , 9 ] Some ACC patients present with fever or local symptoms such as fullness, pain, or a significant mass, while nonfunctional tumors may not be detected until the disease has advanced. [ 10 , 11 ] Surgical resection is the main treatment for ACC patients with no infiltration or metastasis. [ 12 , 13 ] For patients who have developed peripheral tissue infiltration, distant metastasis, or tumor recurrence, surgical resection combined with adjuvant therapy are the primary treatment, although, the effects are often more adverse. [ 14–16 ] The overall prognosis of ACC remains poor, and the 5-year survival rates are about 30%. [ 13 ] Only a few patients with ACC are associated with familial genetic disorders, while disseminated cases are associated with mutations in various genes such as tumor protein p53, catenin beta like 1, menin 1, and cyclin dependent kinase inhibitor 2A. [ 17–19 ] However, the specific pathogenic mechanism of ACC remains unclear. Hence, exploring the diagnostic markers and therapeutic targets for ACC is urgent.

medicine, general & internal